Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab with Carboplatin/Paclitaxel in HER2+ Uterine Serous Papillary Carcinoma
NCT01367002Phase 2Completed
- Sponsor
- Yale University
- Start
- Jun 2011
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in uterine serous carcinoma (USC), sponsored by Yale University. Started Jun 2011; status: completed.
02
Drugs
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT01367002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01367002.